<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065139</url>
  </required_header>
  <id_info>
    <org_study_id>P160951J</org_study_id>
    <secondary_id>2018-004755-20</secondary_id>
    <nct_id>NCT04065139</nct_id>
  </id_info>
  <brief_title>Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study</brief_title>
  <acronym>PIPAC EstoK 01</acronym>
  <official_title>Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study - PIPAC EstoK 01</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritoneal metastasis is a common pattern in advanced gastric cancer leading to a terminal&#xD;
      condition in a very short time. Whatever recent progress regarding systemic chemotherapy&#xD;
      using multi drugs association median survival is limited to 6 months with altered quality of&#xD;
      life (QoL) after 4 months for all patients. We postulated that a new innovative health&#xD;
      technology for delivering intraperitoneal pressurized aerosol of chemotherapy (Doxorubicin&#xD;
      and Cisplatin) during laparoscopy can transform that situation offering to double the&#xD;
      survival with QoL preservation. Interestingly, PIPAC procedure is made to be applied&#xD;
      repeatedly, every 4 to 6 weeks. This therapeutic strategy allows to improved Intra Peritoneal&#xD;
      (IP) drugs impregnation and maintained Intra-Veinous (IV) chemotherapy meanwhile. The primary&#xD;
      objective of this study is to evaluate and compare 24-month progression free-survival in&#xD;
      patients with peritoneal carcinomatosis of gastric cancer treated either with IV chemotherapy&#xD;
      and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) or with IV chemotherapy alone,&#xD;
      with preservation of quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2019</start_date>
  <completion_date type="Anticipated">September 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>24 months</time_frame>
    <description>24-month progression free-survival, defined as time from randomization to any clinical (ascites, abdominal pain, weight loss &gt; 10% of total body weight) and/or morphological signs (systemic metastases, ascites, progression with RECIST criteria) of recurrence (local or systemic) or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain H6</measure>
    <time_frame>6 hours after end of surgery</time_frame>
    <description>Postoperative pain with a numeric rating scale from 0 to 10 (0 being no pain and 10 the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain H12</measure>
    <time_frame>12 hours after end of surgery</time_frame>
    <description>Postoperative pain with a numeric rating scale from 0 to 10 (0 being no pain and 10 the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain H18</measure>
    <time_frame>18 hours after end of surgery</time_frame>
    <description>Postoperative pain with a numeric rating scale from 0 to 10 (0 being no pain and 10 the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain H24</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Postoperative pain with a numeric rating scale from 0 to 10 (0 being no pain and 10 the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain H30</measure>
    <time_frame>30 hours after end of surgery</time_frame>
    <description>Postoperative pain with a numeric rating scale from 0 to 10 (0 being no pain and 10 the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain H36</measure>
    <time_frame>36 hours after end of surgery</time_frame>
    <description>Postoperative pain with a numeric rating scale from 0 to 10 (0 being no pain and 10 the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain H42</measure>
    <time_frame>42 hours after end of surgery</time_frame>
    <description>Postoperative pain with a numeric rating scale from 0 to 10 (0 being no pain and 10 the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain H48</measure>
    <time_frame>48 hours after end of surgery</time_frame>
    <description>Postoperative pain with a numeric rating scale from 0 to 10 (0 being no pain and 10 the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Progression Free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary resectability rate</measure>
    <time_frame>24 months</time_frame>
    <description>Secondary resectability rate after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>monthly until death or 24 months</time_frame>
    <description>Quality of life evaluated monthly by the patient with the EORTC QLQ-STO22 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of health status</measure>
    <time_frame>monthly until death or 24 months</time_frame>
    <description>Quality of health status evaluated monthly by the patient with the EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>60 days</time_frame>
    <description>Rate of treatment-related toxicity at 60 days of each PIPAC procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIPAC success</measure>
    <time_frame>24 hours</time_frame>
    <description>Rate of successful PIPAC procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity Clavien-Dindo</measure>
    <time_frame>60 days</time_frame>
    <description>Morbidity will be evaluated on post-operative day 60 by the Clavien-Dindo classification (I to V)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity Complication Index</measure>
    <time_frame>60 days</time_frame>
    <description>Morbidity will be evaluated by the Comprehensive Complication Index, ranging from 0 to 100 (https://www.assessurgery.com/about_cci-calculator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation</measure>
    <time_frame>24 months</time_frame>
    <description>The time of discontinuation defined as the time from randomization to therapy change or dose reduction because of progression of disease or intolerance or adverse effects or patient refusal or death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Cancer Metastatic</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm : PIPAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pressurized intraperitoneal aerosol chemotherapy (PIPAC)</intervention_name>
    <description>After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.</description>
    <arm_group_label>Experimental Arm : PIPAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard chemotherapy</intervention_name>
    <description>Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 &lt; age ≤ 75 years&#xD;
&#xD;
          -  Performance status (WHO) &lt; 2&#xD;
&#xD;
          -  White blood cells &gt; 3.500 /mm3; neutrophils &gt; 1.500 /mm3; platelets &gt; 100.000 /mm3&#xD;
&#xD;
          -  Creatinemia &lt; 1.5 x Normal, Normal ASAT, ALAT and Serum total bilirubin, Normal ionic&#xD;
             balance (potassium, calcium, magnesium and phosphorus&#xD;
&#xD;
          -  An acceptable nutritional condition with Body Mass Index (BMI) &gt; 18.5 kg/m2, Albumin &gt;&#xD;
             30 g/l, pre-albumin &gt; 110 mg/l&#xD;
&#xD;
          -  Effective contraception for patients of childbearing age&#xD;
&#xD;
          -  Written consent obtained prior any act of the research&#xD;
&#xD;
          -  Patient with social insurance&#xD;
&#xD;
          -  Patient having synchronous or metachronous peritoneal metastasis or ovarian metastasis&#xD;
             of a gastric adenocarcinoma cancer, including adenocarcinoma with independent cells&#xD;
             (ADCI) or linitis&#xD;
&#xD;
          -  Patients with or without primary gastric tumor could be included&#xD;
&#xD;
          -  Peritoneal Cancer Index (PCI) &gt; 8&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight loss &gt; 20% of total body weight before disease&#xD;
&#xD;
          -  Presence of uncontrolled comorbidities including severe chronic disease or organ&#xD;
             insufficiency&#xD;
&#xD;
          -  Contraindication to any drug contained in the chemotherapy regimen, according to&#xD;
             summary of product characteristic's&#xD;
&#xD;
          -  Having any form of previous intra-abdominal chemotherapy or intra-abdominal antibody&#xD;
             therapy&#xD;
&#xD;
          -  Patients with history of allergic reactions to platinum compounds or doxorubicin&#xD;
&#xD;
          -  Complete deficiency of the enzyme dihydropyrimidine dehydrogenase.&#xD;
&#xD;
          -  Patients are not allowed to undergo any cancer-specific treatment during the trial.&#xD;
&#xD;
          -  Secondary debulking surgery is not allowed during PIPAC treatment&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Other systemic metastases (liver, lung, bone, brain) or lombo-aortic lymph node&#xD;
             involvement&#xD;
&#xD;
          -  Pleural effusion requiring evacuation for respiratory failure&#xD;
&#xD;
          -  Small bowel occlusion with no possible food intake&#xD;
&#xD;
          -  Ascites &gt; 3 liters&#xD;
&#xD;
          -  HER2 +++ tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clarisse Eveno, MD, PhD</last_name>
    <phone>320444407</phone>
    <phone_ext>+33</phone_ext>
    <email>clarisse.eveno@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu RESCHE-RIGON, MD PhD</last_name>
    <phone>142499742</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Universitaire Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Clarisse Eveno, MD</last_name>
      <phone>320444407</phone>
      <phone_ext>+33</phone_ext>
      <email>clarisse.eveno@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pressurized intraperitoneal aerosol chemotherapy (PIPAC)</keyword>
  <keyword>gastric adenocarcinoma</keyword>
  <keyword>metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

